Investment Banking

Takeda wins battle for Shire with $62bn deal

Deal marks largest-ever overseas acquisition by a Japanese company

Takeda wins battle for Shire with $62bn deal

Takeda Pharmaceutical has reached an agreement to buy Shire, capping a monthslong battle for control of the European drugmaker and marking the largest-ever overseas acquisition by a Japanese company.

Takeda said it would buy Shire at £49.01 or $66.56 a share — $30.33 in cash and 0.839 Takeda share for each Shire share — valuing the Dublin-based maker of rare treatments at $62bn. Takeda had until Tuesday to formalize an offer, withdraw it or walk away.

WSJ Logo
Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With TrumpExternal link

Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With Trump